Teva announced the U.S. launch of the first generic of Sandostatin LAR Depot (octreotide acetate) for injectable suspension, the long-acting somatostatin analog used in acromegaly and carcinoid-syndrome symptom control. The release cites reference-product annual sales of $826 million as of July 2024 and frames the first-to-market generic as a complex-formulation milestone.
The most-used peptide combinations, what the research actually says, and where to buy — one page, one email.
No spam. Unsubscribe anytime.